Date | Price Target | Rating | Analyst |
---|---|---|---|
8/28/2024 | $130.00 | Equal Weight | Wells Fargo |
7/8/2024 | $125.00 | Outperform | Leerink Partners |
6/3/2024 | $115.00 | Hold | Jefferies |
1/16/2024 | $105.00 → $125.00 | Buy → Neutral | UBS |
1/4/2024 | $88.00 → $125.00 | In-line → Outperform | Evercore ISI |
12/19/2023 | $95.00 | Equal Weight | Wells Fargo |
12/13/2023 | Peer Perform | Wolfe Research | |
9/28/2023 | $133.00 | Outperform | Bernstein |
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
Revenue of $692 million; (2)% reported growth; (1)% organic growth GAAP EPS of $0.45; Adjusted EPS from continuing operations of $1.22 Raises full year 2024 adjusted EPS guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the second quarter ended June 30, 2024. The Company reported GAAP earnings per share of $0.45, as compared to $0.28 in the same period a year ago. GAAP revenue for the quarter was $692 million, as compared to $709 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $86 million, as compared to $78 million for the same period a year ago. GAAP operating profit margin from continuing opera
The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 8, 2024 to all shareholders of record at the close of business on October 18, 2024. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screenin
Revvity, Inc. (NYSE:RVTY), today announced that it will release its second quarter 2024 financial results prior to market open on Monday, July 29, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflo
Revvity, Inc. (NYSE:RVTY), today announced it will present at the following investor conferences in September 2024: 2024 Wells Fargo Healthcare Conference – Boston, MA Wednesday, September 4, 2024 8:45 a.m. ET - Max Krakowiak, senior vice president and chief financial officer 2024 Baird Global Healthcare Conference – New York City, NY Tuesday, September 10, 2024 12:15 p.m. ET - Steve Willoughby, senior vice president, investor relations, ESG, risk Attendees will receive an update on the Company and its strategic priorities. Live audio webcasts will be available on the Events section of the Company's website. Replays of the presentations will be posted on the Revvity Investor Relatio
Revenue of $692 million; (2)% reported growth; (1)% organic growth GAAP EPS of $0.45; Adjusted EPS from continuing operations of $1.22 Raises full year 2024 adjusted EPS guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the second quarter ended June 30, 2024. The Company reported GAAP earnings per share of $0.45, as compared to $0.28 in the same period a year ago. GAAP revenue for the quarter was $692 million, as compared to $709 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $86 million, as compared to $78 million for the same period a year ago. GAAP operating profit margin from continuing opera
The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 8, 2024 to all shareholders of record at the close of business on October 18, 2024. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screenin
10-Q - REVVITY, INC. (0000031791) (Filer)
8-K - REVVITY, INC. (0000031791) (Filer)
11-K - REVVITY, INC. (0000031791) (Filer)
Wells Fargo initiated coverage of Revvity with a rating of Equal Weight and set a new price target of $130.00
Leerink Partners initiated coverage of Revvity with a rating of Outperform and set a new price target of $125.00
Jefferies resumed coverage of Revvity with a rating of Hold and set a new price target of $115.00
Leerink Partners initiates coverage on Revvity (NYSE:RVTY) with a Outperform rating and announces Price Target of $125.
Barclays analyst Luke Sergott maintains Revvity (NYSE:RVTY) with a Equal-Weight and lowers the price target from $116 to $115.
Baird analyst Catherine Ramsey maintains Revvity (NYSE:RVTY) with a Outperform and raises the price target from $126 to $127.